Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.54 |
| ▸ | PDE4A | P27815 | 19/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 18/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 18/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14531563 | 1.00 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6923658 | 0.83 | PDE4A (0.48) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL13986138 | 0.78 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL14531844 | 0.77 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL14260464 | 0.77 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL129356 | 0.72 | PDE4A (0.59) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5704271 | 0.71 | PDE4A (0.57) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL9282814 | 0.71 | PDE4B (0.63) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6172991 | 0.70 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7418485 | 0.70 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822548-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822548-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7825265-B2 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825265-B2 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. (US) | 2010-11-02 | — | — | US | disclosed |
| WO-2008033894-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007056500-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1202955-A4 | 1,4-SUBSTITUTED 4,4-DIARYL CYCLOHEXANES | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6518306-B1 | PDE4 inhibitors particularly in regards to treating allergic and inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2003-02-11 | — | — | US | disclosed |
| EP-1202955-A2 | 1,4-SUBSTITUTED 4,4-DIARYL CYCLOHEXANES | SmithKline Beecham Corporation (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010385-A2 | 1,4-SUBSTITUTED 4,4-DIARYL CYCLOHEXANES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESR2, ESR1, GPER1 | PDE4B 2669/4885PDE4A 2272/4885PDE4C 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.